Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET
Company Participants
Nareg Sagherian - Executive Director, Investor Relations
Jerry Durso - President and CEO
Andrew Saik - Chief Financial Officer
Linda Richardson - Chief Commercial Officer
Michelle Berrey - President, Research & Development and Chief Medical Officer
Conference Call Participants
Yasmeen Rahimi - Piper Sandler
Mayank Mamtani - B. Riley Securities
Ed Arce - H.C. Wainwright
Brian Abrahams - RBC Capital Markets
Jay Olson - Oppenheimer
Jon Wolleben - JMP Securities
Thomas Smith - Leerink Partners
Eliana Merle - UBS
Ryan Deschner - Raymond James
Ritu Baral - Cowen
Matthew Dellatorre - Goldman Sachs
Operator
Hello, and thank you for standing by. Welcome to Intercept Pharmaceuticals Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers presentation, there will be a question-and-answer session. [Operator Instructions]
I would now like to turn the conference over to your speaker Nareg Sagherian. Sir, you may begin.
Nareg Sagherian
Good morning and thank you for joining us on today's call to review Intercept's second quarter 2023 financial results and key business updates.
Our second quarter 2023 press release and accompanying slides are now on our website at intercept pharma.com. Before we begin our discussion, I'd like to note that during our call we will be making forward-looking statements, including statements regarding our approved product and clinical development program, certain regulatory matters and our strategy, prospects, financial guidance and future commercial and financial performance.
Listeners are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this call, and we undertake no obligation to update such statements except as required by law. These forward-looking statements are based on estimates and assumptions that, although believed to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties.
Some, but not necessarily all of the risk factors that could cause our actual results to differ materially from our historical results or those anticipated or predicted by our forward-looking statements are discussed in this morning's press release and in our periodic public filings with the SEC.
Today's call will begin with prepared remarks from our President and CEO, Jerry Durso; Chief Financial Officer, Andrew Saik; Chief Commercial Officer, Linda Richardson; and our President of Research and Development and Chief Medical Officer, Dr. Michelle Berrey. We will then open the call for questions.